In a 17-year-old male with onychomycosis, what is the appropriate oral terbinafine dosing regimen and required laboratory monitoring?

Oral Terbinafine for Onychomycosis in a 17-Year-Old Male

For a 17-year-old male with onychomycosis, prescribe terbinafine 250 mg once daily for 6 weeks for fingernail infection or 12 weeks for toenail infection, with mandatory baseline liver function tests (LFTs) and complete blood count (CBC) before starting treatment. 1

Dosing Regimen

The British Association of Dermatologists guidelines specifically address adolescents in this age range. Since a 17-year-old male typically weighs >40 kg, the adult dosing applies:

• Fingernail onychomycosis: 250 mg once daily for 6 weeks
• Toenail onychomycosis: 250 mg once daily for 12 weeks 1

The guidelines note that for patients >40 kg weight, the 250 mg daily dose is appropriate, which bridges the pediatric and adult recommendations 1.

Required Laboratory Monitoring

Baseline monitoring is mandatory for this patient, even though he falls into a transitional age group:

Pre-Treatment (Required):

• Liver function tests (ALT and AST) 1, 2
• Complete blood count (CBC) 1

The guidelines explicitly state that "baseline liver function tests and a complete full blood count are recommended in paediatric patients as it is unlicensed for use in children" 1. While 17 years approaches adulthood, the unlicensed status in pediatric populations warrants this precautionary monitoring 1.

During Treatment:

No routine monitoring is required during the treatment course for patients without pre-existing conditions 1. However, monitoring becomes necessary if:

• Pre-existing hepatic abnormalities are present
• Concomitant hepatotoxic drugs are used
• Symptoms of hepatotoxicity develop 1

Critical Safety Warnings

Counsel the patient to immediately report and discontinue treatment if experiencing:

• Hepatotoxicity symptoms: Persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, or pale stools 2
• Taste or smell disturbance: Can be severe, prolonged, or permanent 1, 2
• Severe skin reactions: Hives, mouth sores, blistering, peeling skin, facial swelling, difficulty swallowing or breathing 2
• Lupus-like symptoms: Erythema, scaling, photosensitivity 1, 2

Important Clinical Considerations

Terbinafine is the first-line treatment for dermatophyte onychomycosis with Grade A evidence, demonstrating superior efficacy over itraconazole, fluconazole, and griseofulvin 1, 3. The drug achieves mycological cure rates of 70-81% for toenails and 79% for fingernails 3, 4.

Key Advantages:

• Fungicidal (not just fungistatic) activity 1
• Minimal drug-drug interactions (only CYP2D6 substrates) 1, 3
• Persists in nails for 6 months post-treatment 1
• Better tolerability than griseofulvin 3

Common Pitfalls to Avoid:

• Don't skip baseline labs in this age group—the unlicensed pediatric status mandates screening 1
• Warn about permanent taste disturbance upfront—this is rare but can be irreversible 1, 2
• Set realistic expectations: Optimal clinical effect occurs months after treatment completion due to nail growth time 2
• Re-evaluate at 3-6 months post-treatment initiation; consider extending therapy if disease persists 1

Contraindications:

• Active or chronic liver disease 1
• History of allergic reaction to oral terbinafine 2
• Severe renal impairment (requires dose adjustment) 1

The evidence strongly supports continuous daily dosing over pulse regimens for optimal efficacy, with continuous therapy showing 76.67% cure rates versus 26.67% for pulse therapy in recent studies 5.